2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, AML, Translational Research, CML, Study Population, Human, Animal Model
PAPER

4961 Niclosamide enhances AML cell death beyond canonical mitochondrial uncoupling through suppression of apoptotic buffering

Emely Pacheco, Edziu Franczak, PhD2, Brett R Chrest3, Raphael Aruleba4, Polina Krassovskaia, PhD5, Kathleen Sakamoto, MD,PhD6, Kelsey Fisher-Wellman, PhD7
1 Wake Forest University School Of Medicine, Winston-Salem, North Carolina, United States
2 Wake Forest University School Of Medicine, Winston-Salem, North Carolina, United States
3 Wake Forest University School Of Medicine, Winston-Salem, North Carolina, United States
4 Wake Forest University School Of Medicine, Winston-Salem, North Carolina, United States
5 Wake Forest University School Of Medicine, Winston-Salem, North Carolina, United States
6 Stanford University, Stanford, United States
7 Wake Forest University School Of Medicine, Winston-Salem, North Carolina, United States

Acute myeloid leukemia (AML) is associated with a poor prognosis and the treatment leads to significant morbidity. Venetoclax has transformed AML therapy by inhibiting BCL-2 and promoting intrinsic mitochondrial apoptosis, yet the emergence of resistant clones remains the primary cause of treatment failure and mortality. Although resistance is multifactorial, therapy-resistant AML consistently exhibits two linked survival adaptations: maintenance of mitochondrial membrane potential (MMP) and rewiring of the BCL-2 family network. Together, these mechanisms preserve bioenergetic fitness and apoptotic buffering, allowing leukemic cells to remain below the apoptotic threshold and survive mitochondrial stress. Therefore, effective therapies must simultaneously collapse MMP and dismantle the apoptotic defenses that sustain resistance.

Niclosamide is an FDA-approved anthelmintic that acts as a mitochondrial protonophore, uncoupling respiration from ATP synthesis and collapsing MMP. Because AML cells actively maintain MMP to resist mitochondrial stress and apoptosis, we asked whether niclosamide could kill AML cells solely through mitochondrial uncoupling. Consistent with its known mechanism of action, niclosamide increased oxygen consumption and induced rapid, dose-dependent mitochondrial depolarization comparable to other canonical uncouplers (e.g., FCCP, CCCP, and BAM15). However, despite equivalent MMP collapse, niclosamide triggered substantially greater AML cell death. The ability of niclosamide to outperform canonical uncouplers to drive AML cell death was seen in multiple AML cell lines of varying oncogenotypes, as well as a cohort of banked AML patient samples. Together, these findings indicate that niclosamide's anti-leukemic activity extends beyond conventional mitochondrial uncoupling.

The disconnect between MMP collapse and AML cell death suggested that niclosamide disrupts survival pathways beyond mitochondrial uncoupling. Prior studies have shown that niclosamide inhibits several pro-growth/survival signaling pathways, most notably cAMP-response element binding protein (CREB) and STAT3. Importantly, both pathways are known to regulate BCL-2 family expression. Because venetoclax resistance is driven in part by remodeling of the BCL-2 survival network, we next examined whether niclosamide alters apoptotic buffering. Across AML cell lines, niclosamide induced rapid and dose-dependent loss of MCL-1, while BCL-2 and BCL-xL protein levels remained largely unchanged. In contrast, FCCP induced mitochondrial depolarization without equivalently reducing MCL-1 protein abundance, suggesting that the ability of niclosamide to lower MCL-1 is independent of its role as a mitochondrial uncoupler. Given prior evidence that niclosamide inhibits CREB-dependent signaling in AML, we then tested whether CREB inhibition could reproduce this effect. Pharmacologic CREB inhibition reduced MCL-1 expression and sensitized AML cells to canonical mitochondrial uncouplers, supporting a model in which CREB-dependent survival signaling may lie upstream of MCL-1-mediated apoptotic protection during mitochondrial stress. Finally, we asked whether loss of MCL-1 is sufficient to sensitize AML cells to mitochondrial depolarization. Pharmacologic MCL-1 inhibition significantly enhanced the cytotoxicity of canonical uncouplers, partially recapitulating the cell death induced by niclosamide. These findings suggest that MMP collapse lowers the apoptotic threshold, but maximal AML cell death requires simultaneous loss of anti-apoptotic buffering (i.e., loss of MCL-1).

Together, these data support a model in which niclosamide simultaneously targets two critical mechanisms implicated in venetoclax resistance: maintenance of mitochondrial membrane potential and MCL-1-dependent apoptotic protection. By coupling mitochondrial depolarization with loss of MCL-1-mediated buffering, niclosamide may overcome key survival adaptations that enable AML persistence and relapse. These findings provide a mechanistic rationale for ongoing clinical evaluation of niclosamide in relapsed/refractory AML, including the current Phase I trial in pediatric and young adult patients (NCT05188170), and support its continued development as a therapeutic strategy to exploit mitochondrial apoptotic vulnerabilities in resistant disease.

Emely Pacheco: No relevant conflicts of interest to declare.